Al-Rawashde, F.A.; Al-wajeeh, A.S.; Vishkaei, M.N.; Saad, H.K.M.; Johan, M.F.; Taib, W.R.W.; Ismail, I.; Al-Jamal, H.A.N.
Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells. Pharmaceuticals 2022, 15, 1123.
https://doi.org/10.3390/ph15091123
AMA Style
Al-Rawashde FA, Al-wajeeh AS, Vishkaei MN, Saad HKM, Johan MF, Taib WRW, Ismail I, Al-Jamal HAN.
Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells. Pharmaceuticals. 2022; 15(9):1123.
https://doi.org/10.3390/ph15091123
Chicago/Turabian Style
Al-Rawashde, Futoon Abedrabbu, Abdullah Saleh Al-wajeeh, Mansoureh Nazari Vishkaei, Hanan Kamel M. Saad, Muhammad Farid Johan, Wan Rohani Wan Taib, Imilia Ismail, and Hamid Ali Nagi Al-Jamal.
2022. "Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells" Pharmaceuticals 15, no. 9: 1123.
https://doi.org/10.3390/ph15091123
APA Style
Al-Rawashde, F. A., Al-wajeeh, A. S., Vishkaei, M. N., Saad, H. K. M., Johan, M. F., Taib, W. R. W., Ismail, I., & Al-Jamal, H. A. N.
(2022). Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells. Pharmaceuticals, 15(9), 1123.
https://doi.org/10.3390/ph15091123